Apnimed Strengthens Leadership Amid OSA Drug Development
Apnimed hired new leadership to build its capabilities in support of AD109, a potential nighttime oral treatment for OSA currently in phase 3 clinical trials.
Apnimed hired new leadership to build its capabilities in support of AD109, a potential nighttime oral treatment for OSA currently in phase 3 clinical trials.
Apnimed will present new research on drug candidates AD109 and AD113, targeting obstructive sleep apnea, at the European Respiratory Society’s International Congress 2023.
No oral pharmacologic treatment to maintain open airways for people with obstructive sleep apnea has been approved by the FDA—yet.
Topline results from a proof-of-concept randomized, controlled, double-blind, single-dose, crossover study of sleep apnea pill candidates.
Read MoreApnimed announced the dosing of the first patient in a study of the company’s lead investigational oral medication for the treatment of OSA.
Read MoreApnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, has named David P. White, MD, senior vice president of medical affairs. In this role, White will...
Read MoreThe administration of reboxetine plus oxybutynin before bedtime greatly decreased OSA severity and increased next-day vigilance after 1 week.
Read MoreA total of 30 participants will be enrolled. Each participant will receive two different dose levels of AD109, and placebo, at bedtime.
Read MoreApnimed’s AD109 is dosed once-daily at bedtime, designed to treat OSA patients across a broad spectrum of disease severity.
Read MoreIn the phase 1 trial, R-oxybutynin demonstrated a favorable PK profile and was well tolerated with no adverse events.
Read MoreThe disorder has several different causes, researchers are learning. That finding opens the door for personalized therapies—and perhaps even effective drugs.
Read More